Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.33 |
| ▸ | ADH1C | P00326 | 1/20 | 0.33 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | ADH4 | P08319 | 1/20 | 0.33 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 8/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11131762 | 0.98 | SLC2A1 (0.37) | TSHRSLC2A1MEN1CYP2C19KMT2A | |
| SCHEMBL17887519 | 0.88 | LMNA (0.39) | TSHRMEN1KMT2AADH1BADH1C | |
| SCHEMBL7775148 | 0.87 | TSHR (0.39) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL23967590 | 0.86 | LMNA (0.35) | SIGMAR1 | |
| SCHEMBL25971264 | 0.85 | SIGMAR1 (0.42) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL22575458 | 0.85 | TSHR (0.38) | TSHRSLC2A1ADH1BADH1CADH1A | |
| SCHEMBL24337442 | 0.85 | ADRB2 (0.42) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL28726709 | 0.85 | ADRB2 (0.42) | TSHRADH1BADH1CADH1AADH4 | |
| SCHEMBL19285956 | 0.84 | LMNA (0.39) | SLC2A1ADH1BADH1CADH1AADH4 | |
| SCHEMBL25492666 | 0.83 | TSHR (0.43) | TSHRADH1BADH1CADH1AADH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-11028240-B2 | Composite materials with desired characteristics | NANOCORE APS (DK) | 2021-06-08 | — | — | US | disclosed |
| EP-0125093-A1 | Diaz(ep)ine bis(N-amidinoamidine) derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885SLC2A1 4830/4885MEN1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.